<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520610</url>
  </required_header>
  <id_info>
    <org_study_id>AOR 10018</org_study_id>
    <nct_id>NCT01520610</nct_id>
  </id_info>
  <brief_title>TAKO-TSUBO Cardiomyopathy and Genetic</brief_title>
  <official_title>Genetic Polymorphisms in Catecholamine Pathway Responsible for the Tako-TSUBO Cardiomyopathy Susceptibly (TAKO-GENE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a case-control association study with multicentric prospective recruitment.&#xD;
&#xD;
      Tako-TSUBO cardiomyopathy is a new clinical entity mimicking an acute coronary syndrome. It&#xD;
      is characterized by reversible left ventricular dysfunction that is frequently precipitated&#xD;
      by a stressful event and most of patients are postmenopausal women.&#xD;
&#xD;
      Several hypotheses concerning pathogenesis of Tako-TSUBO cardiomyopathy have been proposed,&#xD;
      but at present, exaggerated sympathetic stimulation is the main hypothesis. However, the&#xD;
      investigators don't know why some patients with stressful event may present Tako-TSUBO&#xD;
      cardiomyopathy whereas most of them don't.&#xD;
&#xD;
      The investigators hypothesize that polymorphisms in the genes involved in the adrenergic&#xD;
      pathway resulting in greater catecholamine sensitivity would be associated with an increased&#xD;
      risk of Tako-TSUBO cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that polymorphisms in the genes involved in the adrenergic pathway resulting&#xD;
      in greater catecholamine sensitivity would be associated with an increased risk of Tako-TSUBO&#xD;
      cardiomyopathy.&#xD;
&#xD;
      Aim of this study:&#xD;
&#xD;
      Primary endpoint: Cognitive study aiming at identifying genetic polymorphisms in adrenergic&#xD;
      pathway responsible for the Tako-TSUBO cardiomyopathy susceptibly.&#xD;
&#xD;
      Secondary endpoint: Study of clinical, ECG, angiographic, echocardiographic characteristics&#xD;
      and outcome of patients presenting with Tako-TSUBO cardiomyopathy.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Case-control association study with multicentric prospective recruitment. The study&#xD;
      population will be consisted of 800 Caucasians subjects: 200 patients with Tako-TSUBO&#xD;
      cardiomyopathy and an age- and sex-matched control group (n = 600) of 400 patients with acute&#xD;
      coronary syndrome and 200 patients with stressful event (emergency postoperative patients)&#xD;
      but without Tako-TSUBO cardiomyopathy. Sixteen candidates genes from the catecholamine&#xD;
      pathway will be studied.&#xD;
&#xD;
      The diagnosis of Tako-TSUBO cardiomyopathy will be defined as (1) an acute chest pain during&#xD;
      a stressful incident associated with ST-segment abnormalities and/or increased serum troponin&#xD;
      level, (2) transient left ventricular systolic dysfunction, and (3) no coronary lesions&#xD;
      related to the left ventricular dysfunction.&#xD;
&#xD;
      Diagnosis of acute coronary syndrome will be performed according to the definition of the&#xD;
      American Heart Association/American College of Cardiology and European Society of Cardiology.&#xD;
&#xD;
      We will genotype all the known functional SNPs (Single Nucleotide Polymorphisms) and the Tag&#xD;
      SNPs representative of at least 80% of the total genetic diversity (available at HapMap web&#xD;
      site). SNPs will be studied alone or combined in haplotype.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DNA analysis</measure>
    <time_frame>48 months</time_frame>
    <description>To identify genetic polymorphisms in adrenergic pathway responsible for the Tako-TSUBO cardiomyopathy susceptibly</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis and prognosis of Tako-TSUBO cardiomyopathy</measure>
    <time_frame>48 months</time_frame>
    <description>To assess diagnostic criteria of Tako-TSUBO cardiomyopathy To assess the prognosis of Tako-TSUBO cardiomyopathy</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">530</enrollment>
  <condition>Tako-TSUBO Cardiomyopathy</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>CTT</arm_group_label>
    <description>Patients with cardiopathy of tako TSUBO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCA</arm_group_label>
    <description>Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical stress</arm_group_label>
    <description>patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      20 ml of blood sample will be collected from all patients enrolled in order to DNA analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be consisted of 800 Caucasians subjects: 200 patients with&#xD;
        Tako-Tsubo cardiomyopathy and an age- and sex-matched control group (n = 600) of 400&#xD;
        patients with acute coronary syndrome and 200 patients with stressful event (emergency&#xD;
        postoperative patients) but without Tako-Tsubo cardiomyopathy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        &quot;Tako-TSUBO&quot; group:&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
          -  Patients presenting with Tako-TSUBO cardiomyopathy defined as: 1) an acute chest pain&#xD;
             during a stressful incident associated with ST-segment abnormalities and/or increased&#xD;
             serum troponin level, 2) transient left ventricular systolic dysfunction, and 3) no&#xD;
             coronary lesions related to the left ventricular dysfunction&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Caucasian origin&#xD;
&#xD;
          -  Affiliation to health care system&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Patients presenting with pheochromocytoma&#xD;
&#xD;
          -  Patients presenting with myocarditis&#xD;
&#xD;
          -  Patients presenting with subarachnoid hemorrhage&#xD;
&#xD;
        &quot;Acute coronary syndrome&quot; group (age- and sex-matched control group):&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
          -  Patients presenting with an acute coronary syndrome (according to the definitions of&#xD;
             guidelines)&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
          -  Caucasian origin&#xD;
&#xD;
          -  Affiliation to health care system&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Patients presenting with a suspicion of Tako-TSUBO cardiomyopathy&#xD;
&#xD;
          -  Patients presenting with a history of Tako-TSUBO cardiomyopathy&#xD;
&#xD;
        &quot;Surgical stress&quot; group (age- and sex-matched control group):&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
          -  Patients hospitalized for an urgent surgery&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Caucasian origin&#xD;
&#xD;
          -  Affiliation to health care system&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Patients presenting with increase of troponin after surgery&#xD;
&#xD;
          -  Patients presenting with ECG abnormalities after surgery&#xD;
&#xD;
          -  Patients presenting with a suspicion of Tako-TSUBO cardiomyopathy&#xD;
&#xD;
          -  Patients presenting with a history of Tako-TSUBO cardiomyopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Mansencal, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré. Université de Versailles-Saint Quentin en Yvelines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Name: Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré. Université de Versailles-Saint Quentin en Yvelines</name>
      <address>
        <city>Boulogne Billancourt</city>
        <state>Hautes des Seine</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 23, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tako-TSUBO Cardiomyopathy</keyword>
  <keyword>Stress Cardiomyopathy</keyword>
  <keyword>Myocardiopathies</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Takotsubo Cardiomyopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

